Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Ascending Intravenous Doses of FB825

NCT02309762 is registered in ClinicalTrials.gov with Fountain Biopharma Inc. as lead sponsor.

NCT NCT02309762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02309762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Ascending Intravenous Doses of FB825
Lead sponsor
Fountain Biopharma Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2015
Completion date
February 29, 2016
Enrollment
54 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy